Business Context and Reporting Period
The supplied filing is a MultiPlan Corporation Form 10-Q, not a Claritev Corp filing. It covers the quarter and nine months ended September 30, 2023, with comparable periods ended September 30, 2022. MultiPlan provides data analytics and technology-enabled healthcare cost-management, network, payment-integrity, and revenue-integrity services in the United States.
The company operates as a single reporting segment. It reported 649.5 million Class A shares outstanding as of October 30, 2023.
Financial Performance and Key Metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $242.8 million | $250.5 million | $717.4 million | $838.6 million |
| Operating income | $39.5 million | $36.4 million | $121.2 million | $250.8 million |
| Operating margin | 16.3% | 14.5% | 16.9% | 29.9% |
| Net income (loss) | $(24.1) million | $19.7 million | $(60.3) million | $77.2 million |
| Net margin | (9.9)% | 7.9% | (8.4)% | 9.2% |
| Adjusted EBITDA | $152.3 million | $172.2 million | $461.2 million | $607.2 million |
| Adjusted EPS | $0.06 | $0.09 | $0.18 | $0.39 |
Q3 revenue declined 3.1%, while nine-month revenue declined 14.5%. The nine-month revenue decrease primarily reflected contractual rate changes and lower percentage-of-savings revenue. Operating income increased in Q3 because lower general and administrative expenses more than offset lower revenue and higher service costs, but declined materially for the nine-month period.
Interest expense increased 9.4% in Q3 and 13.1% for the nine-month period, primarily because of higher Term Loan B interest rates. The company recorded a $10.1 million Q3 and $46.9 million nine-month gain from repurchasing debt below carrying value. Changes in the fair value of private placement warrants and unvested founder shares produced a $2.1 million Q3 gain, compared with a $48.9 million gain in the prior-year quarter, and a $0.3 million nine-month loss, compared with a $56.4 million gain in the prior-year period.
Cash Flow, Liquidity, Debt, and Capital Allocation
- Cash and cash equivalents were $101.3 million at September 30, 2023, or $107.6 million including restricted cash, compared with $334.0 million and $340.6 million, respectively, at December 31, 2022.
- Cash provided by operating activities was $144.0 million for the first nine months of 2023, down from $344.7 million in the comparable period.
- Investing cash outflows were $218.4 million, including $77.5 million of property and software investment and $140.9 million for the BST acquisition.
- Financing cash outflows were $158.5 million, including $135.0 million for repurchases of 5.750% Notes, $13.1 million for share repurchases, and $9.9 million of Term Loan B repayments.
- Net long-term debt was $4.558 billion at September 30, 2023, compared with $4.742 billion at December 31, 2022. Principal debt included $1.299 billion of Term Loan B, $1.050 billion of 5.50% Senior Secured Notes, $979.8 million of 5.750% Notes, and $1.300 billion of Senior Convertible PIK Notes, before discounts and issuance costs.
- The Term Loan B interest rate was 9.92% at September 30, 2023. Total debt had an annualized weighted-average cash interest rate of 6.97%, versus 6.22% at September 30, 2022.
- Revolver availability was $442.1 million, with $7.9 million utilized by letters of credit. Management stated that available cash, operating cash flow, and borrowing capacity should provide sufficient liquidity for at least the next twelve months.
- The company entered into interest-rate swaps with an $800 million aggregate notional value, effective August 31, 2023 and maturing August 31, 2026, to reduce floating-rate cash-flow volatility.
Material Changes and Unusual Items
- On May 8, 2023, MultiPlan acquired Benefits Science LLC, or BST, for total consideration of approximately $160.8 million, including $140.9 million of cash and $19.2 million of stock. BST contributed $3.6 million of Q3 revenue and $5.7 million of nine-month revenue; management stated its overall impact was not material through September 30.
- The BST transaction generated $123.8 million of goodwill and $35.7 million of identifiable intangible assets. Potential post-combination retention and incentive payments total $66.0 million at target performance, with up to an additional $16.5 million at maximum performance.
- The company authorized up to $100 million of Class A share repurchases through December 31, 2023 and had spent $13.1 million through September 30. On November 8, 2023, the program was extended through December 31, 2024, leaving up to $86.9 million authorized.
- Medical charges processed increased 9.8% in Q3 and 7.8% for the nine-month period, while potential medical cost savings increased 7.4% and 0.9%, respectively. These measures do not directly equal revenue because customers determine the ultimate claim reductions and fees depend on contract terms.
- The Delaware Stockholder Litigation relating to the 2020 business combination was settled and became final in 2023. The company and insurers paid $33.75 million under the settlement and the company reported the matter as resolved.
- No impairment charges were recorded in the three or nine months ended September 30, 2023. The filing states that disclosure controls were effective and that there were no material changes in internal control over financial reporting.
Outlook, Risks, and Contingencies
The filing does not provide explicit quantitative revenue, earnings, or cash-flow guidance. Management expects existing cash, operating cash flow, and revolver capacity to fund requirements for at least the next twelve months, but notes that future liquidity depends on financial performance, market conditions, lender availability, and access to additional financing.
- Key risks include customer concentration, pricing pressure, reduced healthcare utilization, lower provider discounts, competition, regulatory and healthcare-law changes, cybersecurity or technology disruption, privacy requirements, acquisition integration, employee retention, litigation, and the ability to service substantial debt.
- Three customers accounted for 32%, 20%, and 10% of 2022 revenue, creating material customer-concentration exposure.
- The company remains exposed to floating-rate debt costs despite the new interest-rate swaps. Debt agreements contain restrictions on additional debt, investments, distributions, asset transfers, liens, affiliate transactions, and other actions.
- The consolidated first-lien debt-to-consolidated-EBITDA ratio was 3.63x at September 30, 2023, and the company stated that it was in compliance with all debt covenants.
- Ordinary-course litigation and regulatory matters remain outstanding, although management does not expect them to have a material adverse effect. The filing does not provide a clear aggregate value for all remaining contingencies.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for MultiPlan Corporation, while the request identifies Claritev Corp.
- Reconcile the sharp nine-month revenue decline and determine whether contractual rate changes, customer mix, utilization, or other factors will persist.
- Assess liquidity relative to approximately $4.6 billion of debt, rising interest rates, and scheduled maturities beginning before or around 2027-2028.
- Review the sustainability of operating cash flow after the 58.2% year-over-year decline and after capital expenditures, acquisitions, debt repurchases, and share repurchases.
- Evaluate the economics and integration performance of the BST acquisition, including potential retention payments of up to $82.5 million.
- Review customer concentration, contract-renewal terms, percentage-of-savings estimates, and potential future revenue credits or reversals.
- Verify the impact of the $800 million interest-rate swap portfolio, including hedge effectiveness, collateral requirements, and exposure after its August 2026 maturity.